logo

For the Inventor, By the Inventor

San Francisco, CA, United States of America

89Bio, Inc.


USPTO Granted Patents = 16

% Expired Patents = 6.3



Forward Citations = 31

Loading Chart...
Loading Chart...

19 inventors (with patents filed for the assignee):

goldMedal Robert L Hudkins (8 out of 72 patents)

silverMedal Craig A Zificsak (8 out of 22 patents)

bronzeMedal Bruce D Dorsey (6 out of 54 patents)

4.  Nadine C Becknell (6 out of 20 patents)

5.  Reddeppa Reddy Dandu (6 out of 16 patents)

6.  Linda Weinberg (6 out of 11 patents)

7.  Allison L Zulli (6 out of 30 patents)

8.  Dimitar B Gotchev (6 out of 20 patents)

9.  Boris Schwartsburd (3 out of 5 patents)

10.  Shaji Joseph (3 out of 3 patents)

11.  Melody McWherter (2 out of 9 patents)

12.  David B Whitman (2 out of 9 patents)

13.  Hank Mansbach (2 out of 2 patents)

14.  Chih-Ming Tseng (2 out of 2 patents)

15.  Shawn DeFrees (1 out of 61 patents)


16 patents:

1. 12350314 - Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates (2025-07-08),
2. 12098130 - 1,4-substituted piperidine derivatives (2024-09-24),
3. 12037376 - Methods of treatment using mutant FGF-21 peptide conjugates (2024-07-16),
4. 12036284 - Compositions and methods of treatment for severe hypertriglyceridemia (2024-07-16),
5. 11878982 - Spiropiperidine derivatives (2024-01-23),
6. 11878966 - Substituted 4-benzyl and 4-benzoyl piperidine derivates (2024-01-23),
7. 11850275 - Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates (2023-12-26),
8. 11702388 - 1,4-substituted piperidine derivatives (2023-07-18),
9. 11596669 - Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates (2023-03-07),
10. 11427623 - Methods of treatment using mutant FGF-21 peptide conjugates (2022-08-30),
11. 11046707 - Spiropiperidine derivatives (2021-06-29),
12. 10919875 - Substituted 4-benzyl and 4-benzoyl piperidine derivatives (2021-02-16),
13. 10874714 - Method of treating fibroblast growth factor 21 (FGF-21) deficiency (2020-12-29),
14. 10851057 - 1,4-substituted piperidine derivatives (2020-12-01),
15. 10407479 - Mutant FGF-21 peptide pegylated conjugates and uses thereof (2019-09-10),
Company Overview
89Bio, Inc. is a biotechnology company based in San Francisco, California, focused on developing innovative therapies for liver and metabolic diseases. The company specializes in advancing novel drug candidates that target critical pathways involved in liver function and metabolic regulation. With a commitment to addressing unmet medical needs, 89Bio leverages cutting-edge research and technology to create effective treatment options, aiming to improve patient outcomes in the field of liver health.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

16 Patents

#296 in San Francisco, CA

#4,770 in California

#19,922 in US

#37,831 in the World

San Francisco, CA (US)
San Francisco, CA, United States of America

89Bio, Inc.

Forward Citations = 31

19 inventors:

goldMedal Robert L Hudkins (8 out of 72 patents)

silverMedal Craig A Zificsak (8 out of 22 patents)

bronzeMedal Bruce D Dorsey (6 out of 54 patents)

4.  Nadine C Becknell (6 out of 20 patents)

5.  Reddeppa Reddy Dandu (6 out of 16 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: 89Bio, Inc.. Retrieved from https://idiyas.com/company/89bio

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…